Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study

Wild, Sarah H.; Pierpoint, T; McKeigue, Paul; Jacobs, Howard S.

doi:10.1046/j.1365-2265.2000.01000.x

Cited by 877 publications

(397 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

360

Contrasting

Unclassified

Order By: Relevance

“…This indicates that high LAP levels are associated with MS in PCOS women. IR plays a central role in both the reproductive and metabolic disturbances observed in women with PCOS [ 23 ] . In our study, PCOS women with MS had signifi cantly increased HOMA-IR compared to those without MS.…”

mentioning

confidence: 99%

Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Xiang

Fang

Chen

et al. 2013

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

• ▶ polycystic ovary syndrome • ▶ metabolic syndrome • ▶ lipid accumulation product Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome are exposed to risk factors at a younger age [ 9 ] . Early and accurate identifi cation of high-risk individuals for MS could be important to predict and prevent CVD and type 2 diabetes. There is, therefore, an urgent need to develop a simple, accurate and economic predictor for MS in PCOS. The lipid accumulation product (LAP), which was fi rst described by Kahn [ 10 ] , is based on a combination of waist circumference (WC) and serum triglycerides (TG) and serves as a simple index for lipid over accumulation in adults. High levels of LAP are associated with CVD, impaired glucose tolerance (IGT) and type 2 diabetes [ 11 , 12 ] . In healthy population, LAP is a powerful marker of MS [ 13 , 14 ] , however, to the best of our knowledge, there is currently limited research on the relationship between LAP and MS in women with PCOS. Thus, we aim to investigate the ability of LAP to identify MS in PCOS patients. . It is characterized by hyperandrogenemia, chronic anovulation, and polycystic ovary morphology [ 2 , 3 ] .The etiology of PCOS is still not very clear, however, previous studies have shown that insulin resistance (IR) and central obesity are key pathological factors of PCOS [ 4 , 5 ] . PCOS is not only the reproductive endocrine disease, but also metabolic disorder. Patients with PCOS are often accompanied by metabolic abnormalities, such as dyslipidemia, obesity, and glucose intolerance, which are also components of the metabolic syndrome (MS) [ 6 ] . MS is a cluster of metabolic disorders associated with increased risk of cardiovascular disease (CVD), and central or abdominal obesity is considered a fundamental pathology for the MS. Many of the anthropometric and metabolic abnormalities of PCOS overlap with components of MS, and PCOS patients are at increased risk of having MS [ 7 ] . Adults with MS are at a greater risk of developing CVD [ 8 ] . PCOS women with MS may be at even greater risk for CVD because they Materials and Methods

show abstract

mentioning

confidence: 99%

Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Xiang

Fang

Chen

et al. 2013

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…The risk of type II diabetes (T2D) in women with PCOS is approximately twice that of age-and BMI-matched controls. 2 Although the aetiology of PCOS remains poorly understood, hyperinsulinaemia clearly plays an important role. Measures that reduce insulin resistance and hyperinsulinaemia improve both the metabolic and reproductive features of PCOS.…”

Section: Introductionmentioning

confidence: 99%

Relationship between E23K (an established type II diabetes-susceptibility variant within KCNJ11), polycystic ovary syndrome and androgen levels

et al. 2007

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is strongly associated with hyperinsulinaemia and type II diabetes (T2D). Sequence variation within KCNJ11 (encoding Kir6.2, the beta-cell inwardly rectifying potassium channel) is implicated in the pathogenesis of neonatal diabetes, hyperinsulinaemia of infancy and multifactorial T2D. Comprehensive tagging studies have demonstrated that the KCNJ11 E23K variant (or ABCC8 A1369S in LD40.9) is responsible for the known association between KCNJ11 and T2D. Given the phenotypic overlap between PCOS and T2D, we investigated whether E23K is involved in susceptibility to PCOS and related traits. Case -control analyses for the KCNJ11 E23K variant were performed in (a) 374 PCOS cases and 2574 controls of UK British/Irish origin, and (b) 550 women with PCOS symptoms and 1114 controls from a Finnish birth cohort. The relationship between E23K genotype and androgen levels (a key intermediate phenotype relevant to PCOS) in 1380 samples was studied. The UK case-control analysis revealed no association between E23K genotypes and PCOS status (P ¼ 0.49; Cochran -Armitage test), and no significant relationship between E23K genotype and androgen measures in the samples for which these phenotypes were available (P ¼ 0.19). Similarly, the Finnish case-control analysis showed no association between E23K genotypes and PCOS status (P ¼ 0.75; Cochran -Armitage test), and no significant relationship between E23K genotype and androgen measures in the samples for which these phenotypes were available (Finnish controls, P ¼ 0.25; Finnish cases, P ¼ 0.08). In conclusion, these data (involving 44600 subjects) provide no evidence that common variants of the KCNJ11 E23K polymorphism have a major influence on PCOS susceptibility, though modest effect sizes (ORo1.25) cannot be excluded.

show abstract

“…È stato riportato che il rischio di malattia coronarica e di infarto del miocardio è aumentato in pazienti con PCOS rispetto a donne con cicli regolari [11], anche se la mortalità dovuta a malattia circolatoria non sembra essere incrementata [17].…”

Section: Introduzioneunclassified

“…Recenti studi hanno dimostrato un incremento della prevalenza di CDV in donne con PCOS [14][15][16][17]. Infatti nella PCOS è stata dimostrata disfunzione endoteliale [18) e diastolica [19] ed è stata associata sia ad elevati livelli di androgeni che ad insulino-resistenza.…”

Section: Introduzioneunclassified

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Orio

Cascella

Giallauria

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

RASSEGNA IntroduzioneLa sindrome dell'ovaio policistico (PCOS) è una tra le più comuni patologie endocrine delle donne, essendone affetto il 5-10% delle donne in età riproduttiva [1,2].La PCOS è diagnosticata in presenza di due tra i tre criteri seguenti: 1. ovaie policistiche all'ecografia pelvica 2. oligo-anovulazione 3. evidenza clinica o biochimica di iperandrogenismo (Rottherdam ESHRE-ASRM 2003) [3]. La PCOS non è solo una delle cause principali di infertilità nelle donne, ma è considerata anche una vera e propria sindrome plurimetabolica [2,4,5]: obesità [6], insulino-resistenza [7], dislipidemia [8], alterazione del sistema fibrinolitico [9], sono le conseguenze metaboliche spesso evidenti in questa sindrome.Inoltre, la PCOS è associata a rischi per la salute a lungo termine, inclusi il diabete mellito [10] e la CDV (Malattia Cardiovascolare) [11][12][13][14][15].In particolare l'insulino-resistenza, l'iperandrogenismo e la dislipidemia sono probabilmente tra i maggiori fattori di rischio per l'incidenza della CDV nella PCOS. Tali fattori di rischio cardiovascolare sono spesso evidenti in giovane età, suggerendo che le donne con PCOS, rappresentano un numeroso gruppo di donne in cui è aumentato il rischio di sviluppo precoce di CDV, anche se ciò non è attualmente dimostrato [16].È stato riportato che il rischio di malattia coronarica e di infarto del miocardio è aumentato in pazienti con PCOS rispetto a donne con cicli regolari [11], anche se la mortalità dovuta a malattia circolatoria non sembra essere incrementata [17].Recenti studi hanno dimostrato un incremento della prevalenza di CDV in donne con PCOS [14][15][16][17]. Infatti nella PCOS è stata dimostrata disfunzione endoteliale [18) e diastolica [19] ed è stata associata sia ad elevati livelli di androgeni che ad insulino-resistenza.Di recente, insieme ai classici fattori di rischio CV, come i livelli di colesterolo totale e i livelli di lipoproteine ad alta densità per il colesterolo (HDL-C), l'obesità, l'omocisteina e l'ipertrofia ventricolare sinistra si sono dimostrati essere associati, indipendentemente, ad un incremento del rischio CV [20].

show abstract

Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study

Cited by 877 publications

References 20 publications

Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Relationship between E23K (an established type II diabetes-susceptibility variant within KCNJ11), polycystic ovary syndrome and androgen levels

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Contact Info

Product

Resources

About